TrialAIDS and behavior2025

Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study.

Princy Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.